CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 300 enrolled
Drug / intervention
XIENCE V® Everolimus Eluting Coronary Stent +1 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00180310
NCT00180310Phase 3Completed
CompareCT.gov

A Clinical Evaluation of the XIENCE V® Everolimus Eluting Coronary Stent System in the Treatment of Patients With de Novo Native Coronary Artery Lesions

Abbott Medical Devices·interventional·Posted Sep 16, 2005·Updated Jul 20, 2011

In Brief

A Phase 3 clinical trial evaluating XIENCE V® Everolimus Eluting Coronary Stent and TAXUS™ EXPRESS2™ Paclitaxel Eluting Coronary Stent for Coronary Disease and 2 related conditions. Completed, enrolled 300 participants across 32 sites in 13 countries.

Detailed Summary

Prospective, randomized, active-control, single blind, parallel two-arm multi-center clinical trial comparing XIENCE V® Everolimus Eluting Coronary Stent System to the approved commercially available active control TAXUS™ EXPRESS2™ Paclitaxel Eluting Coronary Stent System. TAXUS™ EXPRESS2™ Paclitaxel Eluting Coronary Stent System is manufactured by Boston Scientific.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCoronary Disease, Coronary Artery Disease, Coronary Restenosis
CountriesAustria, Belgium, Denmark, France, Germany, India, Italy, Netherlands, New Zealand, Poland, South Africa, Spain, Switzerland
Collaborators--

Timeline

Phase 3CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedSep 16, 2005
Enrollment StartJul 1, 2005
Primary CompletionJul 1, 2007
Study CompletionFeb 1, 2011
TodayJul 2, 2026
Enrollment to primary: 2 yearsPosted 20.8 years ago

Interventions

XIENCE V® Everolimus Eluting Coronary Stentdevice

Drug eluting stent implantation stent in the treatment of coronary artery disease.

TAXUS™ EXPRESS2™ Paclitaxel Eluting Coronary Stentdevice

Drug eluting stent implantation stent in the treatment of coronary artery disease